CPIC Warfarin Dosing Guidelines: What Your CYP2C9 and VKORC1 Genes Mean

Warfarin saves lives. It prevents strokes in people with atrial fibrillation, stops blood clots after surgery, and treats deep vein thrombosis. But warfarin is also one of the most dangerous medications in common use - responsible for an estimated 60,000 emergency department visits per year in the United States alone (Budnitz et al., 2011). The difference between a therapeutic dose and a dangerous one can be shockingly small. And your genes play a major role in determining where that line falls.

That's why the Clinical Pharmacogenetics Implementation Consortium (CPIC) recommends using genetic testing to guide warfarin dosing. Specifically, the CPIC warfarin guidelines focus on two genes - CYP2C9 and VKORC1 - that together explain 40–60% of the variation in how much warfarin a person needs (Johnson et al., 2017). If you carry certain variants in these genes, the standard starting dose of 5 mg/day could be far too much - or, less commonly, not enough.

This article breaks down exactly what the CPIC guidelines say, what each gene does, and what your genotype could mean for your warfarin therapy.

How Warfarin Works (and Why Dosing Is So Tricky)

Warfarin is an anticoagulant - it slows blood clotting by interfering with the vitamin K cycle. Your liver uses vitamin K to produce clotting factors (proteins that make blood clot). Warfarin blocks an enzyme called VKORC1 (vitamin K epoxide reductase complex subunit 1), which recycles vitamin K into its active form. Less active vitamin K means fewer clotting factors and thinner blood (Rost et al., 2004).

The problem is that warfarin has an extremely narrow therapeutic index. Doctors measure its effect using the International Normalized Ratio (INR) - a blood test that reflects clotting speed. For most patients, the target INR is 2.0 to 3.0. Below 2.0, you're at risk of clots. Above 3.0, you're at risk of serious bleeding - including hemorrhagic stroke (Ageno et al., 2012).

Stable warfarin doses across the population range from as low as 0.5 mg/day to as high as 20 mg/day - a 40-fold difference. Clinical factors like age, body weight, diet, and other medications explain part of this variation. But genetics explain the largest share.

The Two Genes That Control Your Warfarin Response

Warfarin pharmacogenomics centers on two genes. One controls how quickly your body breaks down the drug. The other controls how sensitive your body is to the drug's effects.

CYP2C9 - How Fast You Break Down Warfarin

The CYP2C9 gene encodes a liver enzyme that metabolizes the more potent form of warfarin (S-warfarin). S-warfarin is 3–5 times more active than R-warfarin, and CYP2C9 is responsible for roughly 80% of its clearance (Rettie et al., 1992).

The normal (wild-type) version of this gene is called CYP2C9*1. Two common variants reduce enzyme function significantly:

• CYP2C9*2 (rs1799853): Reduces warfarin metabolism by approximately 30–50%. Found in about 10–15% of Europeans, but rare in East Asian and African populations (Sanderson et al., 2005).
• CYP2C9*3 (rs1057910): Reduces warfarin metabolism by approximately 90%. Found in about 6–8% of Europeans and 2–4% of Asian populations (Sanderson et al., 2005).

If you carry one or two copies of these variants, warfarin lingers in your system longer, and you need a lower dose to reach the same anticoagulant effect. Carriers of CYP2C9*2 or *3 also face a roughly 1.8- to 1.9-fold increased risk of bleeding events compared to people with the normal genotype (Sanderson et al., 2005).

Additional reduced-function alleles - including CYP2C9*5, *6, *8, and *11 - are more common in people of African descent and are now included in updated CPIC recommendations (Johnson et al., 2017).

VKORC1 - How Sensitive You Are to Warfarin

The VKORC1 gene encodes warfarin's direct molecular target. A single nucleotide variant in the gene's promoter region - VKORC1 c.-1639G>A (rs9923231) - reduces how much VKORC1 protein your body makes. Less target protein means warfarin is more effective at lower doses (Rieder et al., 2005).

This is the single most predictive genetic variant for warfarin dosing genetics:

• GG genotype (normal expression): Requires the highest warfarin doses, typically 5–7 mg/day.
• GA genotype (intermediate expression): Requires moderate doses, typically 3–4 mg/day.
• AA genotype (low expression): Requires the lowest doses, often 1.5–3 mg/day.

The frequency of the A allele varies dramatically across populations. About 37–42% of European-descent individuals carry at least one A allele, while the frequency reaches approximately 89–92% in East Asian populations - which largely explains why East Asian patients typically need lower warfarin doses on average (Limdi et al., 2010).

The VKORC1 variant alone explains approximately 25% of the variability in warfarin dose requirements (Rieder et al., 2005).

What the CPIC Guidelines Recommend

The CPIC guideline for warfarin (Johnson et al., 2017) provides specific, evidence-based recommendations for adjusting warfarin doses based on CYP2C9 and VKORC1 genotypes. Here is what they recommend:

Step 1: Use a validated pharmacogenetic dosing algorithm. The CPIC guidelines recommend calculating the starting dose using an algorithm - such as the one available at warfarindosing.org from the International Warfarin Pharmacogenetics Consortium (IWPC) - that incorporates CYP2C9 genotype, VKORC1 genotype, age, height, weight, race, and concomitant medications (Klein et al., 2009).

Step 2: Apply genotype-based dose adjustments.

For adults without African ancestry:

• Normal metabolizer + VKORC1 GG: Use the calculated algorithm dose (typically 5–7 mg/day)
• CYP2C9 intermediate metabolizer (e.g., *1/*2): Reduce dose by 25–30% from calculated dose
• CYP2C9 poor metabolizer (e.g., *2/*3, *3/*3): Reduce dose by 30–50% from calculated dose
• VKORC1 AA genotype: Already factored into algorithm but expect significantly lower dose requirements
• Combination of CYP2C9 poor metabolizer + VKORC1 AA: Consider starting at the lowest recommended dose and titrating very cautiously

For adults with African ancestry, the guideline additionally recommends factoring in rs12777823 (in the CYP2C cluster), which has a minor allele frequency of about 25% in African Americans and is associated with lower dose requirements (Perera et al., 2013).

Step 3: Monitor closely. Even with genotype-guided dosing, CPIC emphasizes that INR monitoring remains essential - genetics does not eliminate the need for clinical follow-up.

What Your Genotype Means for You

Understanding your warfarin sensitivity gene variants helps you see where you fall on the dosing spectrum:

• CYP2C9 *1/*1 + VKORC1 GG - You're a normal metabolizer with normal warfarin sensitivity. Standard dosing protocols apply. You represent approximately 35–40% of the European-descent population.

• CYP2C9 *1/*1 + VKORC1 GA - Normal metabolism but increased sensitivity. You'll likely need a moderately lower dose than average.

• CYP2C9 *1/*2 + VKORC1 GG - Slightly reduced metabolism, normal sensitivity. May need modest dose reduction (~25%).

• CYP2C9 *1/*3 + VKORC1 GA or AA - Reduced metabolism and increased sensitivity. You may need 40–60% less than the standard dose.

• CYP2C9 *3/*3 + VKORC1 AA - The most sensitive combination. You may require as little as 0.5–2 mg/day. This genotype combination is rare (less than 1% of the population) but carries the highest bleeding risk without dose adjustment.

The EU-PACT randomized controlled trial demonstrated that genotype-guided warfarin dosing increased time spent in therapeutic INR range compared to standard dosing - meaning better anticoagulation with fewer dangerous highs and lows (Pirmohamed et al., 2013).

What You Can Do

If you take warfarin or may need it in the future, here are concrete steps:

1. Talk to your doctor about pharmacogenomic testing. The FDA-approved warfarin label states that CYP2C9 and VKORC1 genotype information, when available, can assist in initial dose selection (FDA, 2010). Many major medical centers now offer pre-treatment genotyping.

2. Check if you already have the data. If you've done consumer genetic testing through 23andMe, AncestryDNA, or similar services, your raw data file likely contains rs1799853 (CYP2C9*2), rs1057910 (CYP2C9*3), and rs9923231 (VKORC1). You can upload your raw DNA file to GenomeInsight to get a full pharmacogenomics report covering warfarin and dozens of other medications.

3. Learn more about how genetics affects your medications. Visit our learning center to understand how pharmacogenomics works and why it matters for personalized medicine.

4. Never adjust your warfarin dose on your own. Genetic information is one input among many. Dose changes should always be made in consultation with your prescribing physician and guided by INR monitoring.

Key Takeaways

• CPIC warfarin guidelines recommend using CYP2C9 and VKORC1 genotype data to calculate personalized starting doses.
• CYP2C9 variants (*2 and *3) reduce warfarin metabolism by 30–90%, requiring lower doses.
• The VKORC1 c.-1639G>A variant increases warfarin sensitivity, with the AA genotype requiring roughly half the standard dose.
• Together, these variants explain 40–60% of individual dose variation.
• Genotype-guided dosing has been shown in clinical trials to improve time in therapeutic range.
• If you have raw DNA data from consumer testing, you can get your warfarin pharmacogenomics profile through GenomeInsight.

References

Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012). Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141(2 Suppl), e52S–e88S.

Budnitz, D. S., Lovegrove, M. C., Shehab, N., & Richards, C. L. (2011). Emergency hospitalizations for adverse drug events in older Americans. New England Journal of Medicine, 365(21), 2002–2012.

FDA. (2010). Coumadin (warfarin sodium) prescribing information. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf

Johnson, J. A., Caudle, K. E., Gong, L., Whirl-Carrillo, M., Stein, C. M., Scott, S. A., Lee, M. T. M., Gage, B. F., Kimmel, S. E., Perera, M. A., Anderson, J. L., Pirmohamed, M., Klein, T. E., Limdi, N. A., Cavallari, L. H., & Wadelius, M. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clinical Pharmacology & Therapeutics, 102(3), 397–404.

Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. T. M., Limdi, N. A., Page, D., Roden, D. M., Wagner, M. J., Caldwell, M. D., & Johnson, J. A. (2009). Estimation of the warfarin dose with clinical and pharmacogenomic data. New England Journal of Medicine, 360(8), 753–764.

Limdi, N. A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D. C., Lee, M. T. M., Chen, C. H., Motsinger-Reif, A., Saber, S., Cooper, G. M., Onuma, T., Mohlke, K., Beasley, T. M., Stein, C. M., & Johnson, J. A. (2010). Warfarin pharmacogenetics: A single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood, 115(18), 3827–3834.

Perera, M. A., Cavallari, L. H., Limdi, N. A., Gamazon, E. R., Konkashbaev, A., Daneshjou, R., Pluzhnikov, A., Crawford, D. C., Wang, J., Liu, N., Tatonetti, N., Kittles, R., Buxbaum, S. G., Ritchie, M. D., Denny, J. C., Crawford, D. C., Johnson, J. A., & Nicolae, D. L. (2013). Genetic variants associated with warfarin dose in African-American individuals: A genome-wide association study. The Lancet, 382(9894), 790–796.

Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., Kesteven, P., Christersson, C., Wahlström, B., Stafberg, C., Zhang, J. E., Leathart, J. B., Kohnke, H., Maitland-van der Zee, A. H., Williamson, P. R., Daly, A. K., Avery, P., Kamali, F., & Wadelius, M. (2013). A randomized trial of genotype-guided dosing of warfarin. New England Journal of Medicine, 369(24), 2294–2303.

Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., & Trager, W. F. (1992). Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chemical Research in Toxicology, 5(1), 54–59.

Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005). Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New England Journal of Medicine, 352(22), 2285–2293.

Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H. J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G. D., Müller, C. R., Strom, T. M., & Oldenburg, J. (2004). Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature, 427(6974), 537–541.

Sanderson, S., Emery, J., & Higgins, J. (2005). CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet systematic review and meta-analysis. Genetics in Medicine, 7(2), 97–104.

---

Related Reading

• CYP2C9 warfarin pharmacogenomics
• pharmacogenomics implementation guide